Zetia Cost in Minnesota 2026: Ezetimibe Prices, Coverage, and Savings Options

What Does Zetia Actually Cost in Minnesota in 2026?

Brand-name Zetia (ezetimibe 10 mg) carries a manufacturer list price of approximately $380 per month in 2026. That number is rarely what Minnesota patients pay. Generic ezetimibe, available from multiple manufacturers, brings the average cash-pay price at Minnesota retail pharmacies to about $15 per month when a free discount card is applied at the counter.

The spread between $380 and $15 is not an accident. Patent expiration on ezetimibe opened the market to generics, and retail competition between pharmacy chains has driven cash prices sharply downward. According to the FDA's current Orange Book, ezetimibe has multiple approved generic manufacturers, meaning supply is stable and prices are unlikely to spike. [1]

Patients who pay the $380 list price are almost always doing so unnecessarily. A pharmacist can substitute a generic automatically in Minnesota under state generic-substitution law, unless a prescriber writes "dispense as written." If your prescription still shows a high price, ask the pharmacist to run it as generic ezetimibe rather than brand Zetia, then apply a GoodRx or RxSaver coupon on top. [2]

The 10 mg once-daily dose is the only approved dose for ezetimibe. No titration is required, which simplifies both prescribing and refill logistics. [3] The FDA label specifies that ezetimibe may be taken with or without food and does not require time-of-day restrictions, making adherence easier than with some statins that carry evening-dosing recommendations. [4]

Why Ezetimibe Is Prescribed: The IMPROVE-IT Evidence Base

Ezetimibe inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% compared with placebo. [5] That mechanism is entirely separate from statin action, so the drugs combine additively rather than redundantly.

The landmark IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the primary composite cardiovascular endpoint (cardiovascular death, major coronary event, or nonfatal stroke) from 34.7% in the simvastatin-only arm to 32.7% in the combination arm over a median 6-year follow-up, an absolute risk reduction of 2.0 percentage points (hazard ratio 0.936, P<0.001). [6] LDL-C fell to a median of 53.7 mg/dL in the combination group versus 69.5 mg/dL on simvastatin alone. [6]

The ACC/AHA 2018 Cholesterol Guideline places ezetimibe as the preferred non-statin add-on for patients who need additional LDL-C lowering beyond maximally-tolerated statin therapy. [7] The guideline states directly: "In patients with clinical ASCVD on maximally tolerated statin therapy who require additional LDL-C lowering, ezetimibe therapy is recommended." [7] That recommendation drives most Minnesota prescriptions for the drug.

Ezetimibe is generally well tolerated. In IMPROVE-IT, rates of muscle-related adverse events and liver enzyme elevations were similar between the combination arm and simvastatin alone. [6] The most commonly reported side effects in clinical trials are upper respiratory infections, diarrhea, and arthralgia, each occurring in fewer than 4% of patients. [3]

Minnesota Medicaid Coverage for Ezetimibe

Minnesota Medicaid (Medical Assistance) covers ezetimibe, but prior authorization is required. PA criteria in Minnesota Medical Assistance generally require documentation that the patient has a qualifying diagnosis (primary hypercholesterolemia or mixed hyperlipidemia), that a statin has been tried or is contraindicated, and that LDL-C remains above goal. [8]

The prior authorization process can take 24 to 72 hours once the prescriber submits a complete PA request. Prescribers filing through the Minnesota DHS electronic PA portal typically receive faster decisions than those submitting by fax. If PA is denied, a prescriber-initiated appeal citing IMPROVE-IT cardiovascular outcomes data and ACC/AHA guideline language has a reasonable probability of reversal, particularly for patients with established ASCVD. [7]

Minnesota Health Care Programs (MHCP) enrollees who are also enrolled in a managed-care plan (such as UCare, Blue Plus, or Hennepin Health) should check their specific plan formulary, because managed-care PA criteria may differ slightly from fee-for-service criteria. Formulary tiers can affect how much of the approved cost the patient shares. [9]

For patients who do not qualify for Medicaid but have low income, Minnesota's MinnesotaCare program and the federally facilitated marketplace plans available through MNsure may cover generic ezetimibe under their formularies with varying cost-sharing. A licensed insurance navigator through MNsure can clarify tier placement for a specific plan before enrollment. [10]

Commercial Insurance and Zetia in Minnesota

Most commercial insurance plans in Minnesota place generic ezetimibe on Tier 1 or Tier 2, which typically means a $10 to $45 copay per 30-day supply depending on plan design. Brand Zetia, if still prescribed, often lands on Tier 3 or Tier 4, where cost-sharing can reach $80 to $150 per month even after insurance. [11]

Large Minnesota employers, including those self-insured under ERISA plans administered by local PBMs such as Prime Therapeutics (headquartered in Eagan, MN), frequently use a preferred-generic step through which brand Zetia requires a PA demonstrating generic failure or intolerance before coverage is approved. Because generic ezetimibe contains the same active molecule at the same 10 mg dose and bioequivalence is FDA-confirmed, "generic failure" is pharmacologically implausible. [1] Clinicians writing "brand medically necessary" should be aware that payers scrutinize these requests closely.

Minnesota residents covered by Medicare Part D should note that generic ezetimibe is on most Part D formularies. The 2024 Inflation Reduction Act drug-price negotiation provisions do not yet directly cap ezetimibe prices under Part D, but the $2,000 annual out-of-pocket cap effective 2025 limits total Part D spending regardless of drug tier. [12] Patients who reach the catastrophic coverage phase now pay $0 for covered Part D drugs. [12]

The HealthRX Step-Down Cost Framework for Minnesota ezetimibe patients moves through four tiers in order: (1) confirm generic dispensing and apply a free retail coupon, targeting $10 to $20 per month; (2) verify commercial insurance tier and request step-edit override if generic is already dispensed; (3) apply for Medicaid or MinnesotaCare if income-eligible; (4) evaluate 503A compounded ezetimibe through a telehealth prescriber if cash-pay remains a barrier. Working through these steps in sequence resolves the cost problem for the majority of patients before reaching the compounding option.

Is Compounded Ezetimibe Legal in Minnesota?

Yes. Compounded ezetimibe is legal in Minnesota when prepared by a licensed 503A compounding pharmacy operating under USP 795 standards and dispensing pursuant to a valid patient-specific prescription. [13] Minnesota Board of Pharmacy regulations align with federal 503A requirements under the Drug Quality and Security Act, meaning the pharmacy must compound based on an individual prescription, not in bulk anticipation of orders. [14]

503A compounding differs from 503B outsourcing facilities. A 503A pharmacy compounds for a specific named patient after a prescription is written. A 503B facility may compound in larger batches for healthcare entities but requires FDA registration and is subject to cGMP standards. [15] Most Minnesota compounding pharmacies dispensing ezetimibe to individual patients operate under 503A, not 503B.

Compounded ezetimibe is not FDA-approved and is not bioequivalence-tested against Zetia in the same way a generic is. The compound may use ezetimibe API (active pharmaceutical ingredient) in capsule or suspension form. Patients should confirm that their compounding pharmacy sources API from an FDA-registered supplier and holds current Minnesota pharmacy licensure, both of which are verifiable through the Minnesota Board of Pharmacy license lookup. [16]

Cost for compounded ezetimibe through a telehealth-connected 503A pharmacy in Minnesota is reported at $0 for qualifying patients enrolled in specific telehealth programs. This typically reflects either a bundled subscription model or program-specific subsidization rather than the literal cost of compounding, which runs $20 to $60 per month for the pharmacy. Patients should ask explicitly whether the $0 price is permanent or introductory. [17]

Telehealth Prescribing of Ezetimibe in Minnesota

Minnesota permits telehealth prescribing of ezetimibe. The state's telehealth parity law (Minn. Stat. section 62A.671) requires commercial insurers to cover telehealth services on the same basis as in-person services, which extends to the prescribing visit required to obtain an ezetimibe prescription. [18] A prescriber conducting a synchronous audio-video visit may write a valid Minnesota ezetimibe prescription without an in-person examination, provided they hold an active Minnesota medical license and comply with standard-of-care requirements for lipid evaluation.

Ezetimibe is a non-controlled substance, so it does not carry the federal DEA in-person requirement that applies to controlled substances like buprenorphine. [19] A Minnesota telehealth prescriber can complete the clinical evaluation (review of lipid panel, cardiovascular risk assessment, contraindication screening) remotely and transmit the prescription electronically to any Minnesota-licensed pharmacy. [20]

HealthRX physicians follow the ACC/AHA 2018 guideline threshold of LDL-C at or above 70 mg/dL in a high-risk ASCVD patient, or LDL-C at or above 100 mg/dL in a moderate-risk patient on maximally-tolerated statin therapy, as the clinical trigger for initiating ezetimibe. [7] A baseline lipid panel is required before prescribing. Patients ordering a lipid panel through a local Minnesota LabCorp or Quest Diagnostics draw site can typically have results within 24 hours and share them securely with a telehealth clinician via patient portal. [21]

Follow-up lipid testing 4 to 12 weeks after starting ezetimibe is standard practice per ACC/AHA guidance, to confirm LDL-C response and ensure no unexpected hepatic signal. [7] Most telehealth platforms that prescribe ezetimibe build the follow-up lab order into their standard protocol.

Discount Programs and Savings Cards for Ezetimibe in Minnesota

Several independent avenues can reduce ezetimibe costs for Minnesota patients outside of insurance.

GoodRx and RxSaver. Free coupon platforms that negotiate rates with retail pharmacy chains. At major Minnesota chains (CVS, Walgreens, Hy-Vee, Thrifty White), GoodRx pricing for generic ezetimibe 10 mg (30 tablets) ranges from approximately $8 to $18 depending on zip code and pharmacy. These coupons cannot be combined with insurance; patients choose one or the other for the transaction. [22]

Merck Patient Assistance. Merck offers the Merck Patient Assistance Program for brand Zetia for uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). Approved patients may receive brand Zetia at no cost. Applications are submitted through Merck's assistance portal or via a licensed clinician's office. [23] Given that generic ezetimibe at $15 per month is clinically equivalent, this program is most relevant to patients who have already been stabilized on brand and do not want a formulation change, or who have documented generic intolerances.

Mark Cuban Cost Plus Drugs. This online pharmacy ships to Minnesota and lists generic ezetimibe at approximately $17 for a 90-day supply as of early 2025, which works out to roughly $5.60 per month, among the lowest cash prices nationally. [24] A valid prescription is required. Shipping typically takes 5 to 7 business days.

Minnesota 340B Network. Federally qualified health centers (FQHCs) and other 340B-eligible entities operating in Minnesota can dispense ezetimibe at 340B ceiling prices to eligible patients, which are substantially below retail. FQHCs in Minneapolis, St. Paul, Duluth, and Rochester participate in 340B. Eligibility is determined by the health center, not the drug manufacturer. [25]

How Ezetimibe Compares to PCSK9 Inhibitors on Cost in Minnesota

When ezetimibe at $15 per month fails to bring LDL-C to goal, the next non-statin option is typically a PCSK9 inhibitor: evolocumab (Repatha) or alirocumab (Praluent). List prices for PCSK9 inhibitors run $550 to $650 per month before insurance. [26] Both carry prior authorization requirements that are considerably more restrictive than those for ezetimibe.

The FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% over a median 2.2 years (HR 0.85, P<0.001) in patients already on optimized statin therapy. [27] Combining ezetimibe with a statin before escalating to PCSK9 inhibition is the standard ACC/AHA sequence because the incremental cost-effectiveness of PCSK9 inhibitors is substantially more favorable when LDL-C is first reduced as far as possible with cheaper agents. [7]

Inclisiran (Leqvio), a small interfering RNA agent dosed twice yearly, received FDA approval in 2021 and represents another option after ezetimibe. [28] Its dosing convenience may appeal to adherence-challenged patients, but Minnesota commercial formulary placements remain restrictive as of 2025. [29] Bempedoic acid (Nexletol), an ATP-citrate lyase inhibitor, is a non-statin oral alternative for truly statin-intolerant patients; the CLEAR Outcomes trial (N=13,970) demonstrated a 13% reduction in major cardiovascular events versus placebo (HR 0.87, P=0.004). [30]

Ezetimibe retains its position as first non-statin add-on because no other agent matches its combination of a $15 monthly cost, a 40-year safety record, once-daily oral dosing, and a randomized trial showing hard cardiovascular endpoint reduction. [6]

Practical Steps for Minnesota Patients Starting Ezetimibe

Getting a prescription filled at the lowest cost in Minnesota requires a short sequence of actions. First, confirm with your prescriber that the prescription reads "ezetimibe 10 mg" (generic) rather than "Zetia" with "dispense as written." Second, before handing the prescription to the pharmacy, check GoodRx, RxSaver, or Cost Plus Drugs for the current price at your preferred location. Third, if you are enrolled in Minnesota Medicaid, ask the pharmacist to bill Medical Assistance directly; if PA is required, your prescriber's office can often submit the request same-day through the DHS portal. [8]

Patients with commercial insurance should ask the pharmacist to run a price comparison between billing insurance and using a cash coupon. In some cases, the cash coupon price of $8 to $18 is lower than the insured copay, and using the coupon does not affect your deductible accumulation (a trade-off worth understanding before choosing). [22]

If cost remains a barrier after these steps, a telehealth appointment with a HealthRX clinician can evaluate whether compounded ezetimibe through a licensed Minnesota 503A pharmacy is appropriate for your situation. The entire process, from lipid panel review to prescription transmission, can be completed in a single 20-minute visit. [18]

A follow-up lipid panel at 6 weeks confirms LDL-C response. The ACC/AHA 2018 guideline target for high-risk ASCVD patients is LDL-C below 70 mg/dL; for very-high-risk patients with two or more major ASCVD events, a target below 55 mg/dL is now endorsed by the European Society of Cardiology, though the ACC/AHA has not formally adopted that threshold. [7, 31]